Abstract
Corticosteroids induce apoptosis in both normal and neoplastic lymphocytes. For this reason they are commonly used to treat autoimmune disorders and lymphoid malignancies also. The exact mechanism of corticosteroid-induced apoptosis is not fully understood despite the fact that much has been found in respect to several supposed involved mechanisms. This process is arbitrarily divided in several phases. Firstly, glucocorticoid enters the cell and binds to the glucocorticoid receptor (GR) in the cytoplasm. The GR changes conformation and the heat shock proteins, normally bound to the receptor in the steady state, fall off. The activated GR-hormone complex enters the nucleus and binds to its specific DNA binding site, the glucocorticoid responsive element (GRE), thus resulting in activating or repressing transcription of genes. The activation of caspases or other proteases and endonucleases finally results in the commitment to cell death.
Keywords: Glucocorticoid, apoptosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Corticoisteroid-Induced Apoptosis in Hematological Malignancies
Volume: 8 Issue: 1
Author(s): Giovanni D'Arena, Nicola Cascavilla, Giovanni Rossi, Aldo Giudice, Claudio Arra, Vincenzo De Feo and Bruno Marcello Fusco
Affiliation:
Keywords: Glucocorticoid, apoptosis
Abstract: Corticosteroids induce apoptosis in both normal and neoplastic lymphocytes. For this reason they are commonly used to treat autoimmune disorders and lymphoid malignancies also. The exact mechanism of corticosteroid-induced apoptosis is not fully understood despite the fact that much has been found in respect to several supposed involved mechanisms. This process is arbitrarily divided in several phases. Firstly, glucocorticoid enters the cell and binds to the glucocorticoid receptor (GR) in the cytoplasm. The GR changes conformation and the heat shock proteins, normally bound to the receptor in the steady state, fall off. The activated GR-hormone complex enters the nucleus and binds to its specific DNA binding site, the glucocorticoid responsive element (GRE), thus resulting in activating or repressing transcription of genes. The activation of caspases or other proteases and endonucleases finally results in the commitment to cell death.
Export Options
About this article
Cite this article as:
D'Arena Giovanni, Cascavilla Nicola, Rossi Giovanni, Giudice Aldo, Arra Claudio, De Feo Vincenzo and Fusco Marcello Bruno, Corticoisteroid-Induced Apoptosis in Hematological Malignancies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580739
DOI https://dx.doi.org/10.2174/187152309787580739 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenesis Activities of Dietary Constituents and Health Foods with Potential Anti-Hepatocellular Carcinoma Activity
Recent Patents on Biomarkers Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer
Recent Patents on Anti-Cancer Drug Discovery The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery